Form 4: Tyra Biosciences Director Nina S. Kjellson Reports Stock Sales

Director Nina S. Kjellson reported the sale of Tyra Biosciences (TYRA) stock held indirectly through investment partnerships.

Summary

• On November 6 and 7, 2024, Nina S. Kjellson, a director of Tyra Biosciences, reported the sale of common stock.
• The sales were executed indirectly through Canaan XI L.P. and 2020+ Co-Investment L.P. Series 7.
• On November 6, 2024, 46,856 shares were sold at a weighted average price of $17.1755, and 5,635 shares were sold at the same weighted average price.
• On November 7, 2024, 19,720 shares were sold at a weighted average price of $17.3181, and 2,371 shares were sold at the same weighted average price.
• Following these transactions, Canaan XI L.P. beneficially owns 3,735,871 shares, and 2020+ Co-Investment L.P. Series 7 beneficially owns 449,258 shares.
• The reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock sales. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Stakeholder Impact

• The stock sales by a director could be perceived negatively by some shareholders, potentially leading to concerns about the company's prospects, although the sales were conducted indirectly through investment partnerships and the director disclaims beneficial ownership except to the extent of their pecuniary interest.

Key Dates